Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth

American Journal of Pathology

Volumn 182, Issue 1, 2013, Pages 84-95

  Xu, Miao ^a   Chen, Xueqin ^a   Chen, Ni ^a   Nie, Ling ^a   Li, Xinglan ^a   Li, Qiuyao ^a   Zeng, Hao ^a   Zhou, Qiao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AZACITIDINE; HARAKIRI PROTEIN; MITOCHONDRIAL PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC THERAPY; HUMANS; MELANOMA; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84871286381     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.09.018     Document Type: Article

References (49)

1. N. Inohara, L. Ding, S. Chen, and G. Nunez harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L) EMBO J 16 1997 1686 1694 (Pubitemid 27151963)
2. J. Sunayama, Y. Ando, N. Itoh, A. Tomiyama, K. Sakurada, A. Sugiyama, D. Kang, F. Tashiro, Y. Gotoh, Y. Kuchino, and C. Kitanaka Physical and functional interaction between BH3-only protein Hrk and mitochondrial pore-forming protein p32 Cell Death Differ 11 2004 771 781 (Pubitemid 39023123)
3. T. Obata, M. Toyota, A. Satoh, Y. Sasaki, K. Ogi, K. Akino, H. Suzuki, M. Murai, T. Kikuchi, H. Mita, F. Itoh, J.P. Issa, T. Tokino, and K. Imai Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer Clin Cancer Res 9 2003 6410 6418 (Pubitemid 38031827)
4. M. Nakamura, E. Ishida, K. Shimada, H. Nakase, T. Sakaki, and N. Konishi Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas Acta Neuropathol 110 2005 402 410 (Pubitemid 41672185)
5. M. Nakamura, E. Ishida, K. Shimada, H. Nakase, T. Sakaki, and N. Konishi Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas Oncology 70 2006 212 221 (Pubitemid 44154695)
6. T. Higuchi, M. Nakamura, K. Shimada, E. Ishida, K. Hirao, and N. Konishi HRK inactivation associated with promoter methylation and LOH in prostate cancer Prostate 68 2008 105 113
7. Y.X. Zeng, K. Somasundaram, and W.S. el-Deiry AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression Nat Genet 15 1997 78 82 (Pubitemid 27014954)
8. S. Huang, D. Jean, M. Luca, M.A. Tainsky, and M. Bar-Eli Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis EMBO J 17 1998 4358 4369 (Pubitemid 28362626)
9. M. Ruiz, C. Pettaway, R. Song, O. Stoeltzing, L. Ellis, and M. Bar-Eli Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells Cancer Res 64 2004 631 638 (Pubitemid 38120903)
10. N. Wajapeyee, R. Britto, H.M. Ravishankar, and K. Somasundaram Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2 J Biol Chem 281 2006 16207 16219
11. D. Jean, J.E. Gershenwald, S. Huang, M. Luca, M.J. Hudson, M.A. Tainsky, and M. Bar-Eli Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells J Biol Chem 273 1998 16501 16508 (Pubitemid 28311434)
12. C. Tellez, M. McCarty, M. Ruiz, and M. Bar-Eli Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma J Biol Chem 278 2003 46632 46642 (Pubitemid 37452239)
13. X. Sun, J.D. Ritzenthaler, X. Zhong, Y. Zheng, J. Roman, and S. Han Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha Cancer Res 69 2009 6445 6453
14. J.E. Gershenwald, W. Sumner, T. Calderone, Z. Wang, S. Huang, and M. Bar-Eli Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo Oncogene 20 2001 3363 3375 (Pubitemid 32588985)
15. N. Wajapeyee, and K. Somasundaram Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition J Biol Chem 278 2003 52093 52101 (Pubitemid 38035795)
16. S. Sumigama, T. Ito, H. Kajiyama, K. Shibata, K. Tamakoshi, F. Kikkawa, T. Williams, M.A. Tainsky, S. Nomura, and S. Mizutani Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha Oncogene 23 2004 5496 5504 (Pubitemid 39044060)
17. N. Jonckheere, V. Fauquette, L. Stechly, N. Saint-Laurent, S. Aubert, C. Susini, G. Huet, N. Porchet, I. Van Seuningen, and P. Pigny Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression Br J Cancer 101 2009 637 644
18. J. Pellikainen, V. Kataja, K. Ropponen, J. Kellokoski, T. Pietilainen, J. Bohm, M. Eskelinen, and V.M. Kosma Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer Clin Cancer Res 8 2002 3487 3495 (Pubitemid 35340726)
19. M. Ruiz, P. Troncoso, C. Bruns, and M. Bar-Eli Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer Clin Cancer Res 7 2001 4086 4095 (Pubitemid 34044632)
20. K.M. Ropponen, J.K. Kellokoski, R.T. Pirinen, K.I. Moisio, M.J. Eskelinen, E.M. Alhava, and V.M. Kosma Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation J Clin Pathol 54 2001 533 538 (Pubitemid 32642942)
21. A.B. Heimberger, E.C. McGary, D. Suki, M. Ruiz, H. Wang, G.N. Fuller, and M. Bar-Eli Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas Clin Cancer Res 11 2005 267 272 (Pubitemid 40075804)
22. J.M. Karjalainen, J.K. Kellokoski, M.J. Eskelinen, E.M. Alhava, and V.M. Kosma Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma J Clin Oncol 16 1998 3584 3591 (Pubitemid 28506772)
23. A. Baldi, D. Santini, T. Battista, E. Dragonetti, G. Ferranti, T. Petitti, A.M. Groeger, A. Angelini, R. Rossiello, F. Baldi, P.G. Natali, and M.G. Paggi Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma J Cell Biochem 83 2001 364 372 (Pubitemid 33027481)
24. C.S. Tellez, D.W. Davis, V.G. Prieto, J.E. Gershenwald, M.M. Johnson, M.F. McCarty, and M. Bar-Eli Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression J Invest Dermatol 127 2007 387 393 (Pubitemid 46106918)
25. C. Bock, S. Reither, T. Mikeska, M. Paulsen, J. Walter, and T. Lengauer BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing Bioinformatics 21 2005 4067 4068 (Pubitemid 41631851)
26. X. Chen, J. Gong, H. Zeng, N. Chen, R. Huang, Y. Huang, L. Nie, M. Xu, J. Xia, F. Zhao, W. Meng, and Q. Zhou MicroRNA145 targets BNIP3 and suppresses prostate cancer progression Cancer Res 70 2010 2728 2738
27. W. Yin, N. Chen, Y. Zhang, H. Zeng, X. Chen, Y. He, X. Wang, and Q. Zhou Surviving nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder Mod Pathol 19 2006 1487 1497 (Pubitemid 44624169)
28. N. Chen, X. Chen, R. Huang, H. Zeng, J. Gong, W. Meng, Y. Lu, F. Zhao, L. Wang, and Q. Zhou BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha} J Biol Chem 284 2009 10004 10012
29. K. Imaizumi, M. Tsuda, Y. Imai, A. Wanaka, T. Takagi, and M. Tohyama Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death J Biol Chem 272 1997 18842 18848 (Pubitemid 27318233)
30. J.E. Young, G.A. Garden, R.A. Martinez, F. Tanaka, C.M. Sandoval, A.C. Smith, B.L. Sopher, A. Lin, K.H. Fischbeck, L.M. Ellerby, R.S. Morrison, J.P. Taylor, and A.R. La Spada Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk J Neurosci 29 2009 1987 1997
31. C. Ma, C. Ying, Z. Yuan, B. Song, D. Li, Y. Liu, B. Lai, W. Li, R. Chen, Y.P. Ching, and M. Li dp5/HRK is a c-Jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons J Biol Chem 282 2007 30901 30909 (Pubitemid 350035234)
32. G.M. Kalinec, M.E. Fernandez-Zapico, R. Urrutia, N. Esteban-Cruciani, S. Chen, and F. Kalinec Pivotal role of Harakiri in the induction and prevention of gentamicin-induced hearing loss Proc Natl Acad Sci U S A 102 2005 16019 16024 (Pubitemid 41552860)
33. E.N. Gurzov, F. Ortis, D.A. Cunha, G. Gosset, M. Li, A.K. Cardozo, and D.L. Eizirik Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis Cell Death Differ 16 2009 1539 1550
34. C. Sanz, A. Benito, N. Inohara, D. Ekhterae, G. Nunez, and J.L. Fernandez-Luna Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells Blood 95 2000 2742 2747 (Pubitemid 30235877)
35. A.L. Bacon, S. Fox, H. Turley, and A.L. Harris Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer Oncogene 26 2007 132 141 (Pubitemid 46067338)
36. B. Brodska, P. Otevrelova, and A. Holoubek Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA Mol Cell Biochem 350 2011 71 80
37. S.P. Garrison, J.R. Jeffers, C. Yang, J.A. Nilsson, M.A. Hall, J.E. Rehg, W. Yue, J. Yu, L. Zhang, M. Onciu, J.T. Sample, J.L. Cleveland, and G.P. Zambetti Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis Mol Cell Biol 28 2008 5391 5402
38. T.Y. Kim, S. Zhong, C.R. Fields, J.H. Kim, and K.D. Robertson Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma Cancer Res 66 2006 7490 7501 (Pubitemid 44289203)
39. E. San Jose-Eneriz, X. Agirre, A. Jimenez-Velasco, L. Cordeu, V. Martin, V. Arqueros, L. Garate, V. Fresquet, F. Cervantes, J.A. Martinez-Climent, A. Heiniger, A. Torres, F. Prosper, and J. Roman-Gomez Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia Eur J Cancer 45 2009 1877 1889
40. I. Sturm, C. Stephan, B. Gillissen, R. Siebert, M. Janz, S. Radetzki, K. Jung, S. Loening, B. Dorken, and P.T. Daniel Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma Cell Death Differ 13 2006 619 627
41. M. Comb, and H.M. Goodman CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2 Nucleic Acids Res 18 1990 3975 3982
42. V.O. Melnikova, A.S. Dobroff, M. Zigler, G.J. Villares, R.R. Braeuer, H. Wang, L. Huang, and M. Bar-Eli CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma PLoS One 5 2010 e12452
43. E. Penna, F. Orso, D. Cimino, E. Tenaglia, A. Lembo, E. Quaglino, L. Poliseno, A. Haimovic, S. Osella-Abate, C. De Pitta, E. Pinatel, M.B. Stadler, P. Provero, M.G. Bernengo, I. Osman, and D. Taverna microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C EMBO J 30 2011 1990 2007
44. T. Hershko, and D. Ginsberg Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis J Biol Chem 279 2004 8627 8634 (Pubitemid 38295917)
45. M.A. Nelson, S.H. Reynolds, U.N. Rao, A.C. Goulet, Y. Feng, A. Beas, B. Honchak, J. Averill, D.T. Lowry, J.R. Senft, A.M. Jefferson, R.C. Johnson, and L.M. Sargent Increased gene copy number of the transcription factor E2F1 in malignant melanoma Cancer Biol Ther 5 2006 407 412
46. A.A. Dar, S. Majid, D. de Semir, M. Nosrati, V. Bezrookove, and M. Kashani-Sabet miR-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 J Biol Chem 286 2011 16606 16614
47. C. Sanz, B. Mellstrom, W.A. Link, J.R. Naranjo, and J.L. Fernandez-Luna Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic Hrk gene in hematopoietic progenitor cells EMBO J 20 2001 2286 2292 (Pubitemid 32410597)
48. C. Sanz, M. Horita, and J.L. Fernandez-Luna Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells Haematologica 87 2002 903 907
49. H. Hao, C. Chen, X.M. Rao, J.G. Gomez-Gutierrez, H.S. Zhou, and K.M. McMasters E2F-1- and E2Ftr-mediated apoptosis: The role of DREAM and HRK J Cell Mol Med 16 2011 605 615